Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

International pharmaceutical expenditure differentials: why?

Michael Dickson1

  • 1University of South Carolina College of Pharmacy, USA.

Managed Care (Langhorne, Pa.)
|April 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Vexing Uncertainty to Intellectual Humility.

Schizophrenia bulletin·2024
Same author

Medicaid Eligibility and Time to Re-incarceration Among Previously Incarcerated Subjects With Schizophrenia.

Journal of health economics and outcomes research·2023
Same author

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

PloS one·2020
Same author

End of an era for erythropoiesis-stimulating agents in oncology.

International journal of cancer·2020
Same author

Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.

Journal of oncology practice·2017
Same author

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

Journal of the National Cancer Institute·2013
Same journal

Thanks to CMS Rule Change, MA Takes SDOH to a Whole New Level.

Managed care (Langhorne, Pa.)·2019
Same journal

Hail, Not Frail! MA's Wellness Reach Expands.

Managed care (Langhorne, Pa.)·2019
Same journal

To Be Continued:The Search for a Cure for HIV.

Managed care (Langhorne, Pa.)·2019
Same journal

Once-a-day HIV Treatment: Pricey But Perhaps Worth It.

Managed care (Langhorne, Pa.)·2019
Same journal

In Trump, HIV/AIDS Groups Find an Ally Who's Tough To Love.

Managed care (Langhorne, Pa.)·2019
Same journal

Air Ambulance Turbulence: Consolidation, Cost Shifting, and Surprise Billing.

Managed care (Langhorne, Pa.)·2019
See all related articles

Drug reimportation policies raise complex questions about drug development costs, intellectual property, and regulatory frameworks. Addressing these issues is crucial for balancing societal benefit with market protections.

Area of Science:

  • Health Policy
  • Pharmaceutical Economics
  • Regulatory Affairs

Background:

  • Drug reimportation presents multifaceted challenges impacting drug development, pricing, and patient access.
  • Existing policies grapple with balancing intellectual property rights against the potential for lower drug costs through international sourcing.

Purpose of the Study:

  • To explore critical policy, regulatory, and market questions surrounding the reimportation of pharmaceutical products.
  • To stimulate further discussion and analysis on the implications of drug reimportation.

Main Methods:

  • A comprehensive review of existing literature and policy frameworks related to drug reimportation.
  • Identification and categorization of key issues across policy, regulatory, and market domains.

Related Experiment Videos

Main Results:

  • Policy questions include funding for new chemical entities (NCEs), value for money, and intellectual property protection.
  • Regulatory questions focus on product provenance, precise definitions of reimportation, and the interplay of state and federal laws.
  • Market issues involve potential U.S. price increases and reciprocal importations by other countries.

Conclusions:

  • Drug reimportation necessitates careful consideration of economic, legal, and logistical factors.
  • Establishing clear regulatory guidelines and liability frameworks is essential for safe and effective reimportation policies.